Joseph Stringer
Stock Analyst at Needham
(4.56)
# 237
Out of 5,090 analysts
323
Total ratings
48.77%
Success rate
37.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Downgrades: Hold | n/a | $220.51 | - | 17 | Nov 14, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $133 → $140 | $122.42 | +14.36% | 9 | Nov 13, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $122 → $120 | $106.01 | +13.20% | 27 | Nov 7, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $78 → $90 | $81.64 | +10.24% | 25 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $65 | $71.53 | -9.13% | 19 | Oct 27, 2025 | |
| MRNA Moderna | Reiterates: Hold | n/a | $25.49 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $30.96 | +13.05% | 24 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $464.56 | +2.89% | 23 | Jul 31, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $14.64 | +91.26% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $6.87 | +103.93% | 18 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $4.52 | +143.63% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $29 | $22.05 | +31.55% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $457.26 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $46.28 | +94.49% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.42 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.30 | +669.23% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $26.59 | +39.18% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $18.68 | -3.64% | 2 | Aug 24, 2021 |
Cidara Therapeutics
Nov 14, 2025
Downgrades: Hold
Price Target: n/a
Current: $220.51
Upside: -
Gilead Sciences
Nov 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $122.42
Upside: +14.36%
Rhythm Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $122 → $120
Current: $106.01
Upside: +13.20%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $78 → $90
Current: $81.64
Upside: +10.24%
Avidity Biosciences
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $71.53
Upside: -9.13%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $25.49
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $30.96
Upside: +13.05%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $464.56
Upside: +2.89%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $14.64
Upside: +91.26%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $6.87
Upside: +103.93%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $4.52
Upside: +143.63%
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $22.05
Upside: +31.55%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $457.26
Upside: -
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $46.28
Upside: +94.49%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.42
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.30
Upside: +669.23%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $26.59
Upside: +39.18%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $18.68
Upside: -3.64%